Evidence map›Paper›PMID 28860486›Full record

ArticleScientific reports2017

A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer.

L Gasa, A Sanchez-Botet, E Quandt, S Hernández-Ortega, J Jiménez, M A Carrasco-García, S Simonetti, S J Kron, M P Ribeiro, E Nadal and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Enhanced Expression ofFrontiers in genetics · 2021
    Article
  7. Atypical cyclins: the extended family portrait.Cellular and molecular life sciences : CMLS · 2020
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

L GasaFaculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.
A Sanchez-BotetFaculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.
E QuandtFaculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.
S Hernández-OrtegaFaculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.
J JiménezFaculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.
M A Carrasco-GarcíaFaculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.
S SimonettiFaculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.
S J KronDepartment of Molecular Genetics and Cell Biology, The University of Chicago, Chicago, USA.
M P RibeiroFaculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain. mpontecardosoribeiro@uic.es.
E NadalDepartment of Medical Oncology and Program in Molecular Mechanisms and Experimental Therapeutics in Oncology, Catalan Institute of Oncology (ICO) Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
A VillanuevaChemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO) Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
J ClotetFaculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain. jclotet@uic.es.
Universitat Internacional de Catalunya · ESHospital General de Catalunya · ESInstitut Català d'Oncologia · ESInstitut d'Investigació Biomédica de Bellvitge · ESUniversity of Chicago · US

Funding

Radiation response within the tumor microenvironmentR01CA164492 · NCI · UNIVERSITY OF CHICAGO · PI KRON, STEPHEN J. · 2011 to 2015
$4.8M
PARP Inhibition To Enhance Induction for Head and Neck CancerR01CA176843 · NCI · UNIVERSITY OF CHICAGO · PI KRON, STEPHEN J. · 2013 to 2016
$1.3M
NCI NIH HHS R01 CA164492NCI NIH HHS R01 CA176843
6 · The paper itself

Abstract

As lung cancer has increased to the most common cause of cancer death worldwide, prognostic biomarkers and effective targeted treatments remain lacking despite advances based on patients' stratification. Multiple core cyclins, best known as drivers of cell proliferation, are commonly deregulated in lung cancer where they may serve as oncogenes. The recent expansion of the cyclin family raises the question whether new members might play oncogenic roles as well. Here, we investigated the protein levels of eight atypical cyclins in lung cancer cell lines and formalin-fixed and paraffin-embedded (FFPE) human tumors, as well as their functional role in lung cancer cells. Of the new cyclins evaluated, CNTD2 was significantly overexpressed in lung cancer compared to adjacent normal tissue, and exhibited a predominant nuclear location. CNTD2 overexpression increased lung cancer cell viability, Ki-67 intensity and clonogenicity and promoted lung cancer cell migration. Accordingly, CNTD2 enhanced tumor growth in vivo on A549 xenograft models. Finally, the analysis of gene expression data revealed a high correlation between elevated levels of CNTD2 and decreased overall survival in lung cancer patients. Our results reveal CNTD2 as a new oncogenic driver in lung cancer, suggesting value as a prognostic biomarker and therapeutic target in this disease.

Indexed as

Up-RegulationA549 CellsAnimalsBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationCyclinsGene Expression Regulation, NeoplasticHumansLung NeoplasmsMaleMiceNeoplasm TransplantationPrognosisSurvival AnalysisBiomarkers, TumorCCNP protein, humanCyclins

Identifiers

PMID28860486
PMCPMC5579190
OpenAlexW2747834091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.